MapLight Therapeutics Inc MPLT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$6.93 up $0.71, 11.41% at close Nov 6
Last close · Previous close $6.22
- Market cap
- At the Nov 6 close
- P/E ratio
- 0.15On last 12 months’ EPS
- Diluted EPS
- $47.30Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$6.93up $0.71, 11.41%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$6.22Nov 5
- Volume501.99KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume374.45KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $6.06 to $40.43; now $6.93
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
MPLT trailed the S&P 500 in all 4 periods.
| Period | MPLT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MPLT: down 28.5% S&P 500: down 5.6% | MPLT trailed the S&P 500 by 22.9 percentage points Trailed |
| 3M | MPLT: down 47.8% S&P 500: down 4.1% | MPLT trailed the S&P 500 by 43.7 percentage points Trailed |
| YTD | MPLT: down 60.5% S&P 500: up 8.7% | MPLT trailed the S&P 500 by 69.2 percentage points Trailed |
| 1Y | MPLT: down 57.1% S&P 500: up 10.9% | MPLT trailed the S&P 500 by 68.0 percentage points Trailed |
$10,000 invested in MPLT a year ago (Nov 6, 2025) would be worth about $4,294 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
MPLT trailed the S&P 500 in all 4 periods.
| Period | MPLT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MPLT: down 28.5% S&P 500: down 5.6% | MPLT trailed the S&P 500 by 22.9 percentage points Trailed |
| 3M | MPLT: down 47.8% S&P 500: down 4.3% | MPLT trailed the S&P 500 by 43.5 percentage points Trailed |
| YTD | MPLT: down 60.5% S&P 500: up 7.8% | MPLT trailed the S&P 500 by 68.3 percentage points Trailed |
| 1Y | MPLT: down 57.1% S&P 500: up 9.7% | MPLT trailed the S&P 500 by 66.8 percentage points Trailed |
$10,000 invested in MPLT a year ago (Nov 6, 2025) would be worth about $4,294 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$39.80
Closing high on . Now 82.6% below that record.
Split-adjusted daily closes since Oct 27, 2025.
Stock splits
MPLT hasn’t split since its price history begins in 2025.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$229.83M
- Diluted EPS
- $47.30
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$19.02M | −$25.08 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$21.23M | −$28.01 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$22.34M | −$29.33 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$29.85M | −$39.11 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$29.42M | −$37.18 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$79.55M | $87.14 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$60.67M | −$1.34 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$60.19M | −$1.32 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY23 (Dec 31, 2023) | $0.00 | −$55.71M | −$5.03 |
| FY24 (Dec 31, 2024) | $0.00 | −$77.58M | −$105.38 |
| FY25 (Dec 31, 2025) | $0.00 | −$161.15M | −$18.56 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$175.12MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$174.67MLast 12 months
- Capital spending$453.00KLast 12 months
Shareholder returns
- $276.74MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $351.55MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$1.99MAs of Jun 30, 2026
- Net cash$349.56MAs of Jun 30, 2026
- 16.52As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −98.6%Last 12 months
Over the last 12 months, MapLight Therapeutics lost money: its net loss was 98.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −60.3%Last 12 months
Over the last 12 months, MapLight Therapeutics’s net loss was 60.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About MapLight Therapeutics Inc
MapLight Therapeutics Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
MPLT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
MPLT stock FAQ
What is MPLT stock’s price today?
MapLight Therapeutics (MPLT) traded at $6.93 at the close on , up $0.71 (11.41%) from the previous close of $6.22. Over the past 52 weeks it has traded between $6.06 and $40.43.
What is MPLT’s P/E ratio?
MPLT trades at 0.1 times its diluted earnings over the four quarters to ($47.30 per share), at the close. (How the P/E ratio works.)
What are MPLT’s earnings per share?
MPLT’s diluted earnings per share were $47.30 over the four quarters to , compared with −$121.53 in the twelve months before. The latest quarter (Q2 FY26) brought −$1.32 per share, against −$39.11 a year earlier (how EPS works).
Does MPLT pay a dividend?
MapLight Therapeutics hasn’t paid a dividend in the last twelve months.
What is MPLT’s 52-week high and low?
Over the past 52 weeks MPLT has traded as low as $6.06 and as high as $40.43. At $6.93 at the close on , it is 82.9% below that high and 14.4% above the low.
What is MPLT’s all-time high?
MPLT’s highest closing price was $39.80 on , adjusted for stock splits. At $6.93 at the close on , it is 82.6% below that record.
Has MPLT stock ever split?
No. MPLT hasn’t split since its price history begins in 2025.
How has MPLT stock performed?
Including dividends and measured to the close on , MPLT has returned −60.5% so far this year and −57.1% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is MapLight Therapeutics in?
MapLight Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does MPLT trade on?
MapLight Therapeutics trades on the Nasdaq under the ticker symbol MPLT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.